 such as tax rate, cyclophosphamide impact, FX and Claris acquisition. 

In conclusion, the performance for the second quarter exceeds expectations with sales increasing 1% on a reported basis and adjusted earnings per diluted share at $0.63, exceeding the guidance of $0.55 to $0.57. Key financial metrics related to adjusted gross margin, adjusted SG&A, transition service income, adjusted R&D spending, net interest expense, adjusted other income, and adjusted tax rate have all been analyzed and discussed in the conference call. The company also provided an updated outlook for 2017 and 2020, with expected sales growth, adjusted operating margins, net interest expense, other income, and adjusted earnings per diluted share. Cash flow performance and long-term financial outlook were also highlighted during the call. The company expects to generate free cash flow of approximately $1.8 billion in 2017 and over $2.6 billion by 2020. The call concluded with an overview of the Q&A session, the company's focus on expense management and further potential enhancements to performance.